Surgery Partners rejected an acquisition offer from UnitedHealth Group, citing regulatory risks and potential delays. Instead, Surgery Partners opted to proceed with an amended merger agreement with HealthSpan Partners, indicating a clear strategic direction away from the larger suitor.
Surgery Partners rejected a $28 per share acquisition bid from UnitedHealth Group, citing significant regulatory risks and potential delays. This decision is a major corporate catalyst for SGRY, as it foregoes a potentially higher valuation from a major player. Instead, Surgery Partners is proceeding with an amended merger agreement with HealthSpan Partners, suggesting a preference for a less complex integration. For traders, this creates short-term uncertainty for SGRY, as the market may react negatively to the rejection of a premium offer, potentially leading to a price correction. UNH's involvement appears to be a non-event for its stock, as they declined to comment and the bid was rejected, indicating no immediate strategic shift or financial outlay.